BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$200.95
3.75 (1.90%)
▲
5d:
+2.73%
30d:
+3.71%
90d:
+9.24%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.4/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BIIB is fairly valued with market pricing in 0.8% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: BIIB is fairly valued with market pricing in 0.8% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$373.97
Based on 14.4% avg growth
INTRINSIC VALUE TODAY
$232.21
13.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $200.94, which is considered extended relative to its 30-day fair value range of $191.31 to $198.25. The stock's valuation (Forward PE: 11.9) is in line with its historical norms (11.6). At these levels, the market is pricing in 0.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a uptrend. The price is approaching resistance at $203.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $220.25 (+11.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BIIB is in a uptrend. The price is approaching resistance at $203.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $220.25 (+11.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$191.31 -
$198.25
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
49.5%
Protect Your Profits
Holding BIIB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($220.25)
- NEUTRAL: Market pricing in 0.8% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$191.31 -
$198.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$193.20
Resistance Level
$203.45
Current Trend
Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.86
Wall Street Target
$220.25
(+11.7%)
Revenue Growth (YoY)
1.9%
Earnings Growth (YoY)
31.1%
Profit Margin
13.8%
Valuation Premium vs History
+0.8% premium
PE vs Historical
11.9 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.8%
(market-implied from PE analysis)
1-Year Target
$198.77
(+1%)
2-Year Target
$200.36
(+2%)
3-Year Target
$201.96
(+2%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$197.51
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 24.8%)
$703.28
(+257%)
Base:
(SPY PE: 11.9, Growth: 24.8%)
$383.01
(+94%)
Bear:
(PE: 10.1, Growth: 24.8%)
$325.55
(+65%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 21.45 | Current EPS (TTM): $9.31
Bull Case
$392.28
(+99%)
Analyst growth 78.6%, PE expands to 23.6
Base Case
$356.62
(+81%)
Market implied 78.6%, PE stable at 21.5
Bear Case
$135.80
(-31%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 3:09 PM ET
Data refreshes hourly during market hours. Next update: 4:09 PM
Data refreshes hourly during market hours. Next update: 4:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
3
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Ro Khanna
SELL
2026-02-06
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 65 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 62 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 59 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
